Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease

J Infect Dis. 2000 Jan;181(1):148-57. doi: 10.1086/315168.

Abstract

Granulocyte colony-stimulating factor (r-met Hu G-CSF; filgrastim; 10 microgram/kg/day for 7 days) was used to mobilize CD34+stem cells into the peripheral blood of human immunodeficiency virus type 1 (HIV-1)-infected individuals and a group of HIV-1-uninfected donors as a measure of immunologic reserve in HIV-1-infected people. G-CSF mobilized CD34+ cells of HIV-1-infected individuals with cell counts >500 CD4+ cells/mm3, as well as in HIV-1-uninfected donors. In contrast, CD34 cell mobilization was significantly blunted in HIV-1-infected individuals with cell counts <500 CD4+ cells/mm3 (<200 cell days vs. >650 cell days, P<.0005, compared with the >500 CD4+ cell cohort). At least 1.75x10(7) CD34 cells were harvested by leukapheresis from patients in each study cohort. CD34+ cell viability and the ability to differentiate precursor cells into myeloid and erythroid progenitor cells were not affected by HIV-1 infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antigens, CD34*
  • CD4 Lymphocyte Count
  • Cohort Studies
  • DNA, Viral / blood
  • Female
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • HIV Infections / immunology*
  • HIV-1*
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Male
  • RNA, Viral / blood
  • Recombinant Proteins
  • T-Lymphocyte Subsets

Substances

  • Antigens, CD34
  • DNA, Viral
  • RNA, Viral
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim